About Sildigra-50 RSM Enterprises
Sildigra-50 is a phosphodiesterase-5 inhibitor formulation containing sildenafil citrate as the active pharmaceutical ingredient. This compound functions through selective inhibition of the cyclic guanosine monophosphate-specific phosphodiesterase type 5 enzyme, which regulates smooth muscle relaxation and vascular tone in preclinical models. Manufactured by RSM Enterprises, this research-grade preparation enables investigators to examine the molecular mechanisms underlying PDE-5 pathway modulation in laboratory environments. The compound demonstrates high selectivity for PDE-5 versus other phosphodiesterase enzymes, making it valuable for studying specific vascular and smooth muscle responses. Research applications span cardiovascular physiology, smooth muscle biology, and cyclic nucleotide signalling pathways. Studies investigating sildenafil citrate have contributed significantly to understanding nitric oxide-mediated vasodilation mechanisms and their therapeutic implications. For comprehensive research chemical access, investigators can explore our complete inventory at Stroid UK Shop, including specialised compounds in our erection drugs category.
Laboratory Applications
Research scientists utilise Sildigra-50 to investigate phosphodiesterase-5 enzyme kinetics, cyclic GMP degradation pathways, and smooth muscle contractility mechanisms in vitro. The compound serves as a valuable tool for examining vascular endothelial function, nitric oxide bioavailability, and arterial compliance in experimental models. Cardiovascular researchers employ this preparation to study flow-mediated dilation responses, endothelial-dependent vasodilation, and the role of PDE-5 in maintaining vascular homeostasis. Pharmacologists investigate the compound’s selectivity profile across different phosphodiesterase isoforms to understand tissue-specific enzyme distribution and function. The research applications extend to examining cellular signalling cascades involving cyclic nucleotide second messengers and their downstream effector pathways. Investigators also study the compound’s effects on platelet aggregation, smooth muscle proliferation, and vascular remodelling processes. For researchers requiring additional modulatory compounds, our SARMs collection and peptides range provide complementary research tools for comprehensive experimental protocols.
Product Specifications
| Product Name | Sildigra-50 RSM Enterprises |
|---|---|
| Active Ingredient | Sildenafil Citrate |
| Strength | 50mg per tablet |
| Manufacturer | RSM Enterprises |
| CAS Number | 171599-83-0 (sildenafil citrate) |
| Molecular Formula | C₂₈H₃₈N₆O₁₁S |
| Molecular Weight | 666.7 g/mol |
| Storage Conditions | Room temperature, dry environment |
| Research Classification | PDE-5 Inhibitor |
The compound exhibits excellent stability under standard laboratory storage conditions and maintains consistent potency throughout its shelf life when stored appropriately. Quality control testing ensures reliable batch-to-batch consistency for reproducible experimental results.
Research Compliance
Sildigra-50 is supplied exclusively for in-vitro laboratory research and analytical testing purposes. This product is not intended for human consumption, therapeutic use, or clinical applications. Researchers must ensure appropriate laboratory safety protocols and institutional approval before conducting studies. All experimental work should comply with relevant research guidelines and institutional review board requirements. Proper handling, storage, and disposal procedures must be followed according to laboratory safety standards and local regulations governing research chemical use.

